CVQ-T NR today 102m at 3.00
Van Sun says CV Technologies gets case of reticence
2006-04-12 09:28 ET - In the News
The Vancouver Sun reports in its Wednesday edition in February, The Sun questioned studies that support the medical value of CV Technologies' COLD-fX product. The Sun's David Baines writes that chief executive officer Jacqueline Shan then launched a counteroffensive. Mr. Shan announced "another clinical study of COLD-fX has met rigorous scientific scrutiny and has been accepted by a peer-reviewed journal for publication." The study is published in the Journal of Alternative and Complementary Medicine. "It is apparent from this study that COLD-fX treatment was effective in reducing the incidence and duration of ARI- [acute respiratory illness] related symptoms in healthy community-dwelling adults aged 65 years and older," it said. Curiously, given such a strong endorsement and the company's practice of using trial results to promote its product, CV Technologies has not reported any of the results in its news releases or advertisements. Mr. Baines also asked several questions about the researchers' methodology and what the researchers specifically intended to measure. He also asked why the study, which was conducted in 1998, is just now being published. In all cases, company officials did not respond.
